IP Library › Granted Patent US 11,434,222
Granted Patent B2
US 11,434,222 · App. 17/524,632 · Granted Sep 6, 2022

MAGL inhibitors

Inventors: John J. M. Wiener (San Diego, CA); Cheryl A. Grice (San Diego, CA); Daniel J. Buzard (San Diego, CA); Justin S. Cisar (San Diego, CA); Olivia Delene Weber (San Diego, CA); Amy Allan (San Diego, CA); Nicholas Raffaele (San Diego, CA); Jeanne Moody (San Diego, CA); Michael B. Shaghafi (San Diego, CA)
Assignee: H. LUNDBECK A/S
C07D401/12A61P25/04A61P25/08C07D221/20C07D401/14C07D405/12C07D413/12C07D417/12C07D471/04C07D487/04C07F9/65583
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,434,222
App. No.
17/524,632
Granted
Sep 6, 2022
Kind
B2
Abstract

Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds and pharmaceutical compositions comprising said compounds. The compounds and compositions provided herein are useful as inhibitors of MAGL. Furthermore, the compounds and compositions as provided herein are useful for the treatment of diseases and disorders benefiting from the inhibition of MAGL.

Claims (89)

1. A compound of Formula (I):

wherein:

R1 is selected from —C(O)NHR2;

R2 is selected from phenyl; 5- or 6-membered heteroaryl, wherein one or two heteroatoms are independently selected from N, O and S; 6-membered heterocycle, wherein one or two heteroatoms are independently selected from N and O; C 3 -C 7 cycloalkyl; and 7 membered bicyclic heterocycle, wherein one or two heteroatoms are independently selected from N and O; and

wherein each phenyl; 5- or 6-membered heteroaryl; 6-membered heterocycle; C 3 -C 7 cycloalkyl; or 7-membered bicyclic heterocycle is unsubstituted or substituted with 1 or 2 substituents independently selected from halogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 3 alkoxy, cyano, —NHC(O)CH 3 , —C(O)NH 2 , —C(O)NHCH 3 , —NHSO 2 CH 3 , —P(O)(CH 3 ) 2 , —OCH 2 COOH, and 5-membered heteroaryl having one or two heteroatoms independently selected from N and O;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , having the structure of Formula (Ia):

wherein:

R1 is selected from —C(O)NHR2;

R2 is selected from phenyl; 5- or 6-membered heteroaryl, wherein one or two heteroatoms are independently selected from N, O and S; 6-membered heterocycle, wherein one or two heteroatoms are independently selected from N and O; C 3 -C 7 cycloalkyl; and 7 membered bicyclic heterocycle, wherein one or two heteroatoms are independently selected from N and O; and

wherein each phenyl; 5- or 6-membered heteroaryl; 6-membered heterocycle; C 3 -C 7 cycloalkyl; or 7-membered bicyclic heterocycle is unsubstituted or substituted with 1 or 2 substituents independently selected from halogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 3 alkoxy, cyano, —NHC(O)CH 3 , —C(O)NH 2 , —C(O)NHCH 3 , —NHSO 2 CH 3 , —P(O)(CH 3 ) 2 , —OCH 2 COOH, and 5-membered heteroaryl having one or two heteroatoms independently selected from N and O;

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R2 is a 5- or 6-membered heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyridazinyl, pyrimidyl, pyrazolyl, thiazolyl, and isoxazolyl, wherein the 5- or 6-membered heteroaryl is unsubstituted or substituted with 1 substituent selected from the group consisting of halogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl, cyclopropyl, C 1 -C 3 alkoxy, cyano, —NHC(O)CH 3 , —C(O)NH 2 , —C(O)NHCH 3 , —NHSO 2 CH 3 , —P(O)(CH 3 ) 2 , —OCH 2 COOH, and 5 membered heteroaryl having 1 or 2 heteroatoms selected independently from N and 0.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R2 is a 6-membered heterocycle selected from the group consisting of tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, wherein the 6-membered heterocycle is unsubstituted or substituted with 1 substituent selected from the group consisting of C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, and cyano.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R2 is a 6-membered heterocycle selected from the group consisting of tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, wherein the 6-membered heterocycle is unsubstituted.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R2 is a 6-membered heterocycle selected from the group consisting of tetrahydro-2H-pyran-4-yl, piperazinyl, and piperidinyl, wherein the 6-membered heterocycle is substituted with 1 substituent selected from the group consisting of C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, and cyano.

7. The compound of claim 1 , wherein the compound is selected from the group consisting of:

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-(dimethylphosphoryl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(pyridin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-(1H-pyrazol-1-yl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-(methylcarbamoyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-methoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((5-fluoropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(pyridin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-7-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(pyrazin-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((5-chloropyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((2-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-(trifluoromethyl)pyridin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-methylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((2-(trifluoromethyl)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(pyrimidin-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((2-(trifluoromethyl)pyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((2-methylpyrimidin-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-methylpyridazin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(pyridazin-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((5-methylpyrazin-2-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((1-methylpiperidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(morpholine-4-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(4-cyanopiperidine-1-carbonyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((1-methyl-1H-pyrazol-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(thiazol-5-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(4-methyltetrahydro-2H-pyran-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((1-methyl-1H-pyrazol-5-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(thiazol-2-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(phenylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(p-tolylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)-1-((3-fluorophenyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate:

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((2-oxaspiro[3.3]heptan-6-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-cyclopropylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-isopropoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-acetamidopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-carbamoylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-(isoxazol-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-(methylsulfonamido)pyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

(±)2-((5-(6-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-6-azaspiro[2.5]octane-1-carboxamido)pyridin-2-yl)oxy)acetic acid; and

1,1,1,3,3,3-hexafluoropropan-2-yl (±)1-((6-cyanopyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein the compound is selected from the group consisting of:

1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-((2-(trifluoromethyl)pyrimidin-4-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-((6-methoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-((6-methoxypyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-((6-methylpyridazin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-((6-methylpyridazin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-(phenylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(phenylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-((6-cyclopropylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-((6-cyclopropylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

1,1,1,3,3,3-hexafluoropropan-2-yl (R)-1-((6-carbamoylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate; and

1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-((6-carbamoylpyridin-3-yl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate;

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 that is 1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(pyridin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 that is 1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 that is 1,1,1,3,3,3-hexafluoropropan-2-yl (S)-1-(isoxazol-4-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate, or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or diluents.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2021
From: WIENER, JOHN J.M.; GRICE, CHERYL A.; BUZARD, DANIEL J.; CISAR, JUSTIN S.; WEBER, OLIVIA DELENE; ALLAN, AMY; RAFFAELE, NICHOLAS; MOODY, JEANNE; SHAGHAFI, MICHAEL B.
To: H. LUNDBECK A/S
Reel/Frame 058321/0222 →
Continuity (2)
Provisional Application 63113662 · Nov 13, 2020
Related Publication 20220153721A1 · May 19, 2022
Cited By (1)
US 12,378,219